CLINICAL NEWS

VTE risk higher with certain oral contraceptives, study finds

Oral contraceptives containing desogestrel, gestodene, or drospirenone could double the risk of venous thromboembolism for women compared with users of contraceptives containing levonorgestrel, according to a Danish study published online October 25 in BMJ. » More

Risk assessment important in VTE prophylaxis for medical inpatients

Hospitalized nonsurgical patients (medical patients and those with acute stroke) should receive pharmacologic venous thromboembolism prophylaxis, unless the risk for bleeding outweighs the likely benefit, according to a new Clinical Practice Guideline from the American College of Physicians. » More

BPA exposure may lead to behavioral, emotional problems in 3 year olds, especially girls

Gestational exposure to bisphenol A (or BPA) may affect the behavior and emotions measured in children aged 3 years, especially girls, according to a study published online October 24 in Pediatrics. » More

FOCUS ON…

Dapagliflozin: An emerging treatment option for type 2 diabetes mellitus. » Click here.

Survey

With specialty pharmacy representing the most rapidly growing component of most pharmacy budgets today, in what specific area do you believe specialty pharmacies most need to expand their service offerings to better support the needs of payers?

a) Improved adherence programming
b) Enhanced safety and outcomes monitoring/reporting
c) More proactive pipeline monitoring and forecasting
d) Advanced healthcare IT to better communicate and integrate care across the healthcare continuum
e) More comprehensive patient/provider education
f) Other

Respond here and see what your colleagues think too.

Want to see the results of our last survey regarding health systems’ oncology medication approval process?
Click here.

FDA ACTIONS

Exenatide injection approved by FDA as adjunct therapy to insulin glargine

FDA has approved exenatide injection (Byetta, Amylin Pharmaceuticals Inc. and Eli Lilly and Co.) as an add-on therapy to insulin glargine for patients with type 2 diabetes who are not achieving adequate glycemic control with the basal insulin analogue alone. » More

FDA approves rivaroxaban to prevent stroke in people with common type of abnormal heart rhythm

FDA has approved rivaroxaban (Xarelto, Janssen Pharmaceuticals) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Xarelto is the only oral anticoagulant approved in the United States that offers once-daily dosing, without the need for routine blood monitoring. » More

FDA approves cetuximab to treat late-stage head and neck cancer

FDA has approved cetuximab (Erbitux, Bristol-Myers Squibb) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer. » More

Resources

•	Drug Watch
•	FDA Actions
•	Latest News
•	Medication Safety
•	Policy Watch

Digital Edition

•	View current edition

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.